Inhalant (red) multi-allergen proprietary drops

Notice of Intent to Sole Source

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. Reference#: N0025919N0091 US Naval Hospital Yokosuka (USNHY) intends to award a firm fixed price sole source contract under the authority of FAR 13.106-1(b)(1)(i), only one source being available to meet the Government's needs, to:

Allergychoices, Inc.

2731 National Drive

Onalaska, WI, 54650-8784

The North American Industry Classification System (NAICS) code for this requirement is 325412; the business size standard is 1250 (# of employees).

The objective of this sole source is to procure Sublingual Immunotherapy Drops used to support patients with allergic rhinitis in support of US Naval Hospital Yokosuka (USNHY).

The requirement is for 120 INHALANT (RED) MULTI-ALLERGEN with delivery schedule from October 1, 2019 to September 30, 2020 (Base Year) plus four (4) option years.

Allergychoices, Inc is the only source that can provide the immunotherapy plans specifically tailored to each patient. Patients are enrolled in an immunotherapy care plan that takes up to 5 years to complete. USNH Yokosuka (USNHY) cannot switch to another medication provider and interrupt ongoing patient care because of contracting restrictions. Treatment is an ongoing process for 30 patients currently enrolled in immunotherapy care plan. Patients are placed on a specific treatment protocol with new vials of drops provide every 3 months. The process of vetting new companies, requiring in having to repeat allergy testing and obtain new vials of drops for every patient would negatively result in a break of therapy for all . This compromises the effectiveness of treatment and poses a significant setback for patients relying on allergy therapy to control their symptoms.

This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work and are able to provide valid certification to provide Sublingual Immunotherapy Drops validated by Allergychoices, Inc. Capability statements shall not exceed 6 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.

Capability statements are due by 11:00 am Pacific Time, August 28th, 2019. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: mildred.k.pollard-hueitt.civ@mail.mil . The email subject line shall state, "US Naval Hospital Yokosuka (USNHY), Special Notice Number N0025919N0091."

NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED

.